Globus Medical (GMED) Misses Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Aegis Capital Reiterates Buy on Globus Medical (GMED) Following 4Q EPS Miss
February 28, 2017 7:45 AM ESTAegis Capital reiterated a Buy rating and $31.00 price target on Globus Medical (NYSE: GMED) following the company's 4Q earnings report. Sales grew 6.3% to $151.6 million, driven by Alphatec international sales and recovery in the US market. Non-GAAP EPS of $0.31 was 2 cents short of consensus estimates. Management reiterated FY2017 guidance of $625 million (including a $5 million FX headwind) and non-GAAP EPS of... More
